CHIANTALL PARAS: Open Payments
NPI 1194489435 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$698 in 20 payments from 15 companies in 2025. Trend: 2023 $434 · 2024 $1,279 · 2025 $698
Food & beverage: $521Education: $177
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $208 |
| PFIZER INC. | 1 | $86 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| ABBVIE INC. | 2 | $52 |
| Janssen Biotech, Inc. | 2 | $47 |
| Merck Sharp & Dohme LLC | 1 | $31 |
| Secura Bio, Inc. | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| Incyte Corporation | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
Products named: Trodelvy, ADCETRIS, SCEMBLIX, KEYTRUDA, COPIKTRA, XPOVIO, JAKAFI, CALQUENCE.
Industry payments across CA — which companies pay providers there.
